Compare Amgen, Inc. (AMGN) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Zillow Group Inc Class A — how do they compare? Amgen, Inc. trades at $357.49 (market cap $196.12B), while Zillow Group Inc Class A trades at $31.61 (market cap $7.36B). The key difference: Amgen, Inc. is far larger — about 26.6× Zillow Group Inc Class A's market cap, and Amgen, Inc. pays a 2.77% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| AMGN | ZG | |
|---|---|---|
Market Cap | $196.12B | $7.36B |
Sector | Health | Media |
52-Week High | $388.16 | $86.76 |
52-Week Low | $271.18 | $29.14 |
Enterprise Value | $241.41B | $7.00B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Zillow Group (ZG) trades at $32.00, down 3.64% on the day, with a neutral technical signal and mixed earnings history. The company reported a return to profitability in 2025 with net income of $23 million, though valuation ratios like a P/E of 128 remain elevated. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautiously optimistic given analyst consensus targets near $57.80, but risks from litigation and competitive pressures in the real estate tech sector warrant attention. Revenue growth and execution on profitability targets are key catalysts for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
